ACIU vs. TSVT, ME, ALDX, CDT, VSTM, QURE, OVID, PBYI, ACRV, and XBIT
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include 2seventy bio (TSVT), 23andMe (ME), Aldeyra Therapeutics (ALDX), Conduit Pharmaceuticals (CDT), Verastem (VSTM), uniQure (QURE), Ovid Therapeutics (OVID), Puma Biotechnology (PBYI), Acrivon Therapeutics (ACRV), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune (NASDAQ:ACIU) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment.
AC Immune currently has a consensus price target of $16.00, indicating a potential upside of 537.45%. 2seventy bio has a consensus price target of $13.17, indicating a potential upside of 184.99%. Given AC Immune's stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than 2seventy bio.
AC Immune has higher earnings, but lower revenue than 2seventy bio. AC Immune is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
AC Immune received 230 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 62.32% of users gave AC Immune an outperform vote while only 58.97% of users gave 2seventy bio an outperform vote.
AC Immune has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, 2seventy bio has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.
51.4% of AC Immune shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 2.6% of 2seventy bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, AC Immune had 4 more articles in the media than 2seventy bio. MarketBeat recorded 5 mentions for AC Immune and 1 mentions for 2seventy bio. 2seventy bio's average media sentiment score of 1.17 beat AC Immune's score of 1.09 indicating that 2seventy bio is being referred to more favorably in the news media.
AC Immune has a net margin of 0.00% compared to 2seventy bio's net margin of -216.73%. AC Immune's return on equity of -37.51% beat 2seventy bio's return on equity.
Summary
AC Immune beats 2seventy bio on 11 of the 18 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
